Skip to main content
ALTERITY THERAPEUTICS LIMITED logo

ALTERITY THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · ATH ISIN · AU0000043945 LEI · 52990045JUZVZ9QL3159 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country AU Australia
Listing ASX ATH

About ALTERITY THERAPEUTICS LIMITED

https://alteritytx.com/

Alterity Therapeutics Limited is a clinical-stage company focused on developing disease-modifying therapies for neurodegenerative disorders. The company's research and development efforts center on addressing the underlying pathology of conditions such as Multiple System Atrophy (MSA) and Parkinson's disease. Its lead therapeutic candidate, ATH434, is an orally administered small molecule designed to redistribute excess iron in the brain, thereby inhibiting the aggregation of alpha-synuclein and reducing oxidative stress. By targeting these specific mechanisms, the company aims to preserve neuronal integrity and slow the progression of parkinsonian diseases. Alterity utilizes a specialized platform to identify compounds that modulate metal-protein interactions, focusing on first-in-class treatments for orphan diseases with high unmet medical needs.

Recent filings

Filing Released Lang Actions
Alterity Data Supports ATH434 Phase 3 Advancement in MSA 6 pages 275.7KB
Regulatory Filings Classification · 85% confidence The document is a press release announcing clinical data presentations at medical conferences and plans for Phase 3 development. It does not contain financial statements, management discussion of results, a proxy solicitation, earnings highlights, or a detailed investor slide deck. It is a general corporate announcement with forward-looking statements, serving as a catch-all press release rather than a specific regulatory filing or report. Therefore, it falls under the fallback category for miscellaneous regulatory announcements.
2026-05-18 English
Corporate Presentation May 2026 46 pages 3.4MB
Investor Presentation Classification · 93% confidence The document is a slide deck titled “Corporate Presentation” by Alterity Therapeutics, containing forward‐looking statements, strategic overview, clinical program details, efficacy data, development pipeline, and trial results. It is clearly an investor‐oriented presentation rather than a regulatory filing, earnings release, or full financial report. Therefore, it matches the definition of an Investor Presentation (IP).
2026-05-11 English
Alterity Announces Publication on MRI as Biomarker for MSA 5 pages 251.3KB
Regulatory Filings Classification · 38% confidence The document is a corporate press release announcing the publication of a peer‐reviewed scientific study in NeuroImage. It contains no financial results, no management or board changes, no regulatory filing or offering details, and no report itself—it simply announces a publication. It does not fit specific categories like earnings release, annual/interim report, proxy, M&A, etc. Therefore it falls into the fallback “Regulatory Filings” category (RNS) for miscellaneous corporate announcements.
2026-05-10 English
Alterity to Deliver Presentations at May Medical Meetings 3 pages 215.6KB
Investor Presentation Classification · 90% confidence The document is a press release announcing that Alterity Therapeutics will deliver presentations at multiple medical conferences in May 2026. It lists the titles, presenters, dates, and locations of these presentations. There is no financial data, no detailed report content, no regulatory filing, no voting results, no management changes, no earnings data, and no legal or capital structure information. The document is an announcement of upcoming presentations rather than a report or transcript. It is not a report publication announcement since it does not mention any report being published or attached. Therefore, the document best fits the category of Investor Presentation (IP) as it relates to company presentations focused on development programs and clinical updates for investors and the public.
2026-05-06 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 449.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update' and contains detailed financial data including cash flow statements for the quarter ending 31 March 2026. It includes operational cash flows, investing and financing activities, and a corporate update with management and board changes. The presence of substantive financial data for a quarterly period, along with detailed analysis and commentary, indicates this is a comprehensive interim/quarterly financial report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-29 English
Consolidation/Split - ATH 10 pages 33.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3A.3 - Notification of security consolidation or split' and contains detailed information about a security consolidation event for ALTERITY THERAPEUTICS LIMITED. It includes specifics such as the consolidation ratio, record dates, approval details, and changes in the number of securities and exercise prices before and after consolidation. The content is focused on the reorganization of the company's securities rather than financial results, management changes, or other report types. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues, stock splits, or other capital changes. The document is substantive and not merely an announcement of a report, so it is not an RPA or RNS. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2026-04-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.